文献库 文献相关信息

题目:
LCN2 Promoter Methylation Status as Novel Predictive Marker for Microvessel Density and Aggressive Tumor Phenotype in Breast Cancer Patients.
作者:
Meka(Phanni bhushann),Jarjapu(Sarika),Nanchari(Santhoshi Rani),Vishwakarma(Sandeep Kumar),Edathara(Prajitha Mohandas),Gorre(Manjula),Cingeetham(Anuradha),Vuree(Sugunakar),Annamaneni(Sandhya),Dunna(Nageswara Rao),Mukta(Srinivasulu),B(Triveni),Satti(Vishnupriya)
状态:
发布时间2015-07-12 , 更新时间 2016-11-25
期刊:
Asian Pac J Cancer Prev
摘要:
LCN2 (Lipocalin 2) is a 25 KD secreted acute phase protein, reported to be a novel regulator of angiogenesis in breast cancer. Up regulation of LCN2 had been observed in multiple cancers including breast cancer, pancreatic cancer and ovarian cancer. However, the role of LCN2 promoter methylation in the formation of microvessels is poorly understood. The aim of this study was to analyze the association of LCN 2 promoter methylation with microvessel formation and tumor cell proliferation in breast cancer patients. The LCN2 promoter methylation status was studied in 64 breast cancer tumors by methylation specific PCR (MSP). Evaluation of microvessel density (MVD) and Ki67 cell proliferation index was achieved by immunohistochemical staining using CD34 and MIB-1 antibodies, respectively. LCN2 promoter unmethylation status was observed in 43 (67.2%) of breast cancer patients whereas LCN2 methylation status was seen in 21 (32.8%). Further, LCN2 promoter unmethylation status was associated with aggressive tumor phenotype and elevated mean MVD in breast cancer patients.
语言:
eng
DOI:

联系方式

山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼

电话: 0531-88819269

E-mail: product@genelibs.com

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。